Skip to the stories
Wednesday, 18 November 2026
Saved

Next edition

7:42

Headlines

Top Stories

FDA approves novel Bayer drug Sunharbo to reduce recurrent stroke risk

The Food and Drug Administration approved Bayer's new medication Sunharbo, which prevents recurrent strokes without increasing bleeding risks.

FTMQ Health, written by our newsroom0 views

Share
Picture: STAT News

The United States Food and Drug Administration approved a new medication from Bayer on Monday to reduce the recurrence of stroke. STAT News and UA.NEWS both reported that the drug, which will be marketed under the brand name Sunharbo, represents the first entry in a novel class of blood thinners designed to prevent clot formation without increasing the risk of bleeding. [1][3]

Many traditional blood thinners are not prescribed to stroke patients because of concerns over bleeding risks. According to STAT News, Sunharbo targets stroke prevention by inhibiting factor XIa, a specific protein mechanism thought to stop harmful blood clots while avoiding additional bleeding dangers. [1]

STAT News reported that in a Phase 3 clinical trial involving human participants who had previously suffered a stroke and were receiving standard stroke therapies, 8.4 percent of participants experienced positive outcomes with the new treatment approach. [1]

Bayer previously commercialized acetylsalicylic acid under the trademark Aspirin in 1899, which established a major milestone in mass-produced pain relievers. The pharmaceutical firm also manufactures other oral anticoagulant medications, including rivaroxaban, which is sold under the brand name Xarelto to treat deep vein thrombosis and pulmonary emboli. [4][5]

Share

In short

  • The FDA approved Bayer's new drug Sunharbo on Monday to prevent recurrent strokes.
  • Sunharbo inhibits protein XIa to prevent dangerous blood clots without raising bleeding risks.
  • In a Phase 3 trial of people taking common stroke treatments, 8.4 percent of participants achieved positive results.

Sources

Every paragraph above points to the numbered items it rests on. Read the originals here.

  1. [1]STAT+: FDA approves novel Bayer drug to reduce recurrence of strokeSTAT News, 8d ago (the report this story comes from)
  2. [2]FDA approves novel Bayer drug to reduce recurrence of strokeSTAT, 8d ago
  3. [3]FDA approves Bayer’s Sunharbo to reduce recurrent stroke risk — STAT NewsUA.NEWS, 8d ago

Background

  1. [4]Rivaroxaban on Wikipedia
  2. [5]Bayer on Grokipedia

Our newsroom writes these reports with the help of software, from the 5 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.

Earlier reports of ours on the same people and subjects.

More in Top Stories

Get the day in one email

Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments

Loading

Join the conversation

Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.

Already on the list? Enter the same address and we will send a sign-in link.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.